{
  "id": 863984,
  "title": "Bora Q2 2026 slides show strong rebound, revenue miss weighs",
  "url": "https://urgent.news/2026/08/14/bora-q2-2026-slides-show-strong-rebound-revenue-miss-weighs",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-14T11:08:59.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/bora-q2-2026-slides-show-strong-rebound-revenue-miss-weighs-93CH-4860370"
  },
  "original_language": "en",
  "account": "On August 13, Bora Pharmaceuticals released its Q2 2026 financial results, displaying a remarkable recovery with earnings growth tripling, although the company underperformed revenue forecasts. Investors reacted negatively, pushing Bora's shares down 3.08% to $409. The presentation demonstrated the company's evolution from a generics-focused manufacturer to a diversified pharmaceutical entity with expanding specialty drug, CDMO, and consumer healthcare divisions. CEO Bobby Sheng highlighted the company's rebound from a planned quarter one slowdown, citing maintenance and supply chain challenges. Despite a 58% revenue shortfall, Bora's adjusted earnings per share reached $5.34, surpassing the forecasted $4.79 by 11.5%. Revenue of $2.3 billion significantly fell short of the estimated $5.48 billion. Q2 2026 results showed robust sequential improvements across vital metrics, with revenue hitting NT$5,889 million, a 47% increase from Q1 and 21% year-over-year growth. The business mix shifted, with CDMO accounting for 36% of revenue, pharma sales at 50%, and consumer healthcare at 14%. Revenue from CDMO surged 40.2% sequentially and 33% year-over-year, while pharma sales grew by 30.4%. Consumer Healthcare showed explosive growth of 234% year-over-year and 354% sequentially. Bora's cash position improved to NT$8,431 million, up from NT$4,832 million in Q1 2026, attributed to preparations for the Rockville acquisition from MacroGenics. The net debt-to-equity ratio decreased to 71.3%, reflecting a five-quarter trend of debt reduction. The CDMO segment emerged as a primary growth driver, boasting a record backlog of US$317 million and new contract wins totaling US$378.2 million.",
  "summary": null,
  "key_points": [
    "Bora Pharmaceuticals reports Q2 2026 earnings with tripled growth, missing revenue forecasts",
    "Revenue of $2.3 billion falls short of estimated $5.48 billion",
    "CDMO segment emerges as primary growth driver with record backlog of $317 million"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}